Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Operating Leases (2022 - 2025)

Atara Biotherapeutics' Operating Leases history spans 4 years, with the latest figure at $9.3 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 68.75% year-over-year to $9.3 million; the TTM value through Dec 2025 reached $9.3 million, down 68.75%, while the annual FY2025 figure was $9.3 million, 68.75% down from the prior year.
  • Operating Leases reached $9.3 million in Q4 2025 per ATRA's latest filing, down from $15.0 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $64.0 million in Q2 2022 to a low of $9.3 million in Q4 2025.
  • Average Operating Leases over 4 years is $38.4 million, with a median of $40.4 million recorded in 2024.
  • Peak YoY movement for Operating Leases: surged 214.66% in 2023, then plummeted 68.75% in 2025.
  • A 4-year view of Operating Leases shows it stood at $58.1 million in 2022, then fell by 21.31% to $45.7 million in 2023, then crashed by 34.53% to $29.9 million in 2024, then tumbled by 68.75% to $9.3 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Operating Leases are $9.3 million (Q4 2025), $15.0 million (Q3 2025), and $15.4 million (Q2 2025).